Peripheral T cell lymphoma: clinical utility of romidepsin

Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sawey K, Zain J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/18e68f7822e04f3f895597494ad165b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:18e68f7822e04f3f895597494ad165b5
record_format	dspace
spelling	oai:doaj.org-article:18e68f7822e04f3f895597494ad165b52021-12-02T02:48:55ZPeripheral T cell lymphoma: clinical utility of romidepsin1179-9889https://doaj.org/article/18e68f7822e04f3f895597494ad165b52012-06-01T00:00:00Zhttp://www.dovepress.com/peripheral-t-cell-lymphoma-clinical-utility-of-romidepsin-a10099https://doaj.org/toc/1179-9889Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant tumor cells after exposure to conventional chemotherapy have led researchers to study indirect targets, like the tumor vasculature. A more recent indirect approach involves targeting the epigenetic modifiers, DNA methyltransferase and histone deacetylase. Histone deacetylase inhibitors have been shown to be active cytotoxic agents in T cell lymphoma. The current treatments approved by the US Food and Drug Administration for relapsed cutaneous T cell lymphoma are vorinostat and romidepsin. The diversity and rarity of peripheral T cell lymphomas present a challenge for effective treatment. With their poor overall survival rate, new targeted therapies need to be developed.Keywords: peripheral T cell lymphoma, treatment, romidepsinSawey KZain JDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 109-115 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Sawey K Zain J Peripheral T cell lymphoma: clinical utility of romidepsin
description	Jasmine Zain, Kathryn SaweyNYU Langone Medical Center, New York, USAIntroduction: Direct therapeutic targets, such as aberrant tumor cell genes and tumor cell markers, have been the focus of cancer treatment for more than 50 years. The resulting damage to normal cells and emergence of drug-resistant tumor cells after exposure to conventional chemotherapy have led researchers to study indirect targets, like the tumor vasculature. A more recent indirect approach involves targeting the epigenetic modifiers, DNA methyltransferase and histone deacetylase. Histone deacetylase inhibitors have been shown to be active cytotoxic agents in T cell lymphoma. The current treatments approved by the US Food and Drug Administration for relapsed cutaneous T cell lymphoma are vorinostat and romidepsin. The diversity and rarity of peripheral T cell lymphomas present a challenge for effective treatment. With their poor overall survival rate, new targeted therapies need to be developed.Keywords: peripheral T cell lymphoma, treatment, romidepsin
format	article
author	Sawey K Zain J
author_facet	Sawey K Zain J
author_sort	Sawey K
title	Peripheral T cell lymphoma: clinical utility of romidepsin
title_short	Peripheral T cell lymphoma: clinical utility of romidepsin
title_full	Peripheral T cell lymphoma: clinical utility of romidepsin
title_fullStr	Peripheral T cell lymphoma: clinical utility of romidepsin
title_full_unstemmed	Peripheral T cell lymphoma: clinical utility of romidepsin
title_sort	peripheral t cell lymphoma: clinical utility of romidepsin
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/18e68f7822e04f3f895597494ad165b5
work_keys_str_mv	AT saweyk peripheraltcelllymphomaclinicalutilityofromidepsin AT zainj peripheraltcelllymphomaclinicalutilityofromidepsin
_version_	1718402087409156096

Peripheral T cell lymphoma: clinical utility of romidepsin

Ejemplares similares